home / stock / algs / algs quote
Last: | $0.8101 |
---|---|
Change Percent: | 2.01% |
Open: | $0.829 |
Close: | $0.8101 |
High: | $0.85 |
Low: | $0.7811 |
Volume: | 185,331 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.8101 | $0.829 | $0.8101 | $0.85 | $0.7811 | 185,331 | 05-03-2024 |
$0.846 | $0.7522 | $0.846 | $0.871 | $0.7522 | 326,243 | 05-02-2024 |
$0.77 | $0.75 | $0.77 | $0.7896 | $0.75 | 84,256 | 05-01-2024 |
$0.765 | $0.742 | $0.765 | $0.788899 | $0.74 | 181,103 | 04-30-2024 |
$0.7338 | $0.782 | $0.7338 | $0.8199 | $0.7266 | 139,465 | 04-29-2024 |
$0.782 | $0.818 | $0.782 | $0.8341 | $0.77 | 110,840 | 04-26-2024 |
$0.818 | $0.81 | $0.818 | $0.829 | $0.782 | 133,487 | 04-25-2024 |
$0.829 | $0.8153 | $0.829 | $0.8699 | $0.7896 | 644,248 | 04-24-2024 |
$0.8236 | $0.8015 | $0.8236 | $0.8977 | $0.8015 | 96,855 | 04-23-2024 |
$0.801 | $0.7551 | $0.801 | $0.81 | $0.74 | 470,064 | 04-22-2024 |
$0.75 | $0.77 | $0.75 | $0.8 | $0.73 | 141,291 | 04-19-2024 |
$0.7931 | $0.7888 | $0.7931 | $0.825 | $0.758 | 239,328 | 04-18-2024 |
$0.787 | $0.811 | $0.787 | $0.8454 | $0.7868 | 124,541 | 04-17-2024 |
$0.835 | $0.891 | $0.835 | $0.91 | $0.8 | 247,328 | 04-16-2024 |
$0.8947 | $1.01 | $0.8947 | $1.02 | $0.87 | 329,067 | 04-15-2024 |
$1 | $1.05 | $1 | $1.08 | $0.9962 | 294,101 | 04-12-2024 |
$1.06 | $1.02 | $1.06 | $1.09 | $1.02 | 356,580 | 04-11-2024 |
$1.04 | $1.05 | $1.04 | $1.08 | $0.99 | 347,862 | 04-10-2024 |
$1.06 | $1.03 | $1.06 | $1.1 | $1.02 | 237,444 | 04-09-2024 |
$1.07 | $1.02 | $1.07 | $1.09 | $1.02 | 336,769 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Aligos Therapeutics Inc. Company Name:
ALGS Stock Symbol:
NASDAQ Market:
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmace...
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it...